These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37577753)

  • 21. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.
    Le Guiner C; Servais L; Montus M; Larcher T; Fraysse B; Moullec S; Allais M; François V; Dutilleul M; Malerba A; Koo T; Thibaut JL; Matot B; Devaux M; Le Duff J; Deschamps JY; Barthelemy I; Blot S; Testault I; Wahbi K; Ederhy S; Martin S; Veron P; Georger C; Athanasopoulos T; Masurier C; Mingozzi F; Carlier P; Gjata B; Hogrel JY; Adjali O; Mavilio F; Voit T; Moullier P; Dickson G
    Nat Commun; 2017 Jul; 8():16105. PubMed ID: 28742067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; McDonald CM; Smith EC; Zaidman CM; Nakagawa T; ; Hoffman EP
    J Neuromuscul Dis; 2023; 10(3):439-447. PubMed ID: 37005891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy.
    Hibma JE; Jayachandran P; Neelakantan S; Harnisch LO
    CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):375-386. PubMed ID: 36718719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests.
    Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP
    Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration.
    Siemionow M; Biegański G; Niezgoda A; Wachowiak J; Czarnota J; Siemionow K; Ziemiecka A; Sikorska MH; Bożyk K; Heydemann A
    Stem Cell Rev Rep; 2023 Nov; 19(8):2724-2740. PubMed ID: 37707670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the relationship between North Star Ambulatory Assessment and Health Utilities Index scores in Duchenne muscular dystrophy.
    Audhya I; Rogula B; Szabo SM; Feeny D; Bolatova T; Gooch K
    Health Qual Life Outcomes; 2023 Jul; 21(1):76. PubMed ID: 37468890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; McDonald CM; Smith EC; Zaidman CM; Nakagawa T; ; Hoffman EP
    J Neuromuscul Dis; 2022; 9(4):493-501. PubMed ID: 35634851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy.
    Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
    Bourke JP; Bueser T; Quinlivan R
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
    Zhang C; Feng HY; Huang SL; Fang JP; Xiao LL; Yao XL; Chen C; Ye X; Zeng Y; Lu XL; Wen JM; Zhang WX; Li Z; Feng SW; Xu HG; Huang K; Zhou DH; Chen W; Xie YM; Xi J; Zhang M; Li Y; Liu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Aug; 22(4):399-405. PubMed ID: 16086277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up.
    Heydemann A; Bieganski G; Wachowiak J; Czarnota J; Niezgoda A; Siemionow K; Ziemiecka A; Sikorska MH; Bozyk K; Tullius SG; Siemionow M
    Stem Cell Rev Rep; 2023 Jul; 19(5):1340-1359. PubMed ID: 37000376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
    JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
    McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
    J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.
    Finkel RS; Flanigan KM; Wong B; Bönnemann C; Sampson J; Sweeney HL; Reha A; Northcutt VJ; Elfring G; Barth J; Peltz SW
    PLoS One; 2013; 8(12):e81302. PubMed ID: 24349052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial.
    McDonald CM; Shieh PB; Abdel-Hamid HZ; Connolly AM; Ciafaloni E; Wagner KR; Goemans N; Mercuri E; Khan N; Koenig E; Malhotra J; Zhang W; Han B; Mendell JR;
    J Neuromuscul Dis; 2021; 8(6):989-1001. PubMed ID: 34120909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.
    Shin JH; Pan X; Hakim CH; Yang HT; Yue Y; Zhang K; Terjung RL; Duan D
    Mol Ther; 2013 Apr; 21(4):750-7. PubMed ID: 23319056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial.
    Servais L; Mercuri E; Straub V; Guglieri M; Seferian AM; Scoto M; Leone D; Koenig E; Khan N; Dugar A; Wang X; Han B; Wang D; Muntoni F;
    Nucleic Acid Ther; 2022 Feb; 32(1):29-39. PubMed ID: 34788571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
    Cirak S; Arechavala-Gomeza V; Guglieri M; Feng L; Torelli S; Anthony K; Abbs S; Garralda ME; Bourke J; Wells DJ; Dickson G; Wood MJ; Wilton SD; Straub V; Kole R; Shrewsbury SB; Sewry C; Morgan JE; Bushby K; Muntoni F
    Lancet; 2011 Aug; 378(9791):595-605. PubMed ID: 21784508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.